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Materials and Methods 
 
General  
NMR spectra were recorded on a Varian Gemini 2000 NMR spectrophotometer at 300 MHz for 
1H and 75 MHz for 13C with TMS as an internal standard. EI mass spectra were recorded on a 
Finnigan MAT SSQ 710. MALDI spectra were recorded on a 4.7 T Ultima Fourier transform 
Mass spectrometer (IonSpec, Irvine, CA). Melting points were determined in a Büchi melting 
point apparatus. The silica gel (0.040–0.063 mm) used for column chromatography was 
purchased from Merck. Microanalyses were carried out at Chemical Laboratory II at University 
of Copenhagen, Denmark. 
Cell-based assays 
Compounds, Cells and Viruses 
Compounds were dissolved in DMSO at 100 mM and then diluted in culture medium. 
Cell lines were purchased from American Type Culture Collection (ATCC). The absence of 
mycoplasma contamination was checked periodically by the Hoechst staining method. Cell lines 
supporting the multiplication of RNA viruses were the CD4+ human T-cells containing an 
integrated HTLV-1 genome (MT-4). 
Cytotoxicity Assays 
For cytotoxicity evaluations, exponentially growing cells derived from human haematological 
tumors [CD4+ human T-cells containing an integrated HTLV-1 genome (MT-4)] were seeded at 
an initial density of 1×105 cells/mL in 96 well plates in RPMI-1640 medium supplemented with 
10% fetal calf serum (FCS), 100 units/mL penicillin G and 100 µg/mL streptomycin. Cell cultures 
were then incubated at 37°C in a humidified, 5% CO2 atmosphere in the absence or presence of 
serial dilutions of test compounds. Cell viability was determined after 96 h at 37°C by the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) method .[21] 
Antiviral assays 
Activity of compounds against Human Immunodeficiency virus type-1 (HIV-1) was based on 
inhibition of virus-induced cytopathogenicity in MT-4 cells acutely infected with a multiplicity of 
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infection (m.o.i.) of 0.01. Briefly, 50 L of RPMI containing 1x104 MT-4 were added to each well 
of flat-bottom microtitre trays containing 50 L of RPMI, without or with serial dilutions of test 
compounds. Then, 20 L of an HIV-1 suspension containing 100 CCID50 were added. After 4-
day incubation, cell viability was determined by the MTT method. 
 
Synthetic Procedures 
 
General procedure for the synthesis of 2-(6-chloro-2-(dimethylamino)-5-methylpyrimidin-
4-yl)-2-(aryl)acetonitriles 2a-c: To a mixture of compound 1 (1.0 g, 5.0 mmol) and the 
appropriate benzyl cyanide derivative (5.5 mmol) in dry dimethylformamide (20 mL) was added 
sodium hydride (55% suspension in paraffin oil, 0.655 g, 15.0 mmol) portionwise at room 
temperature. After stirring for 1 h under dry conditions, the reaction mixture was quenched by 
addition of water (2 mL) dropwise. Then the solution was poured on cold water (50 mL) and 
neutralized with 4M hydrochloric acid. Then ether (40 mL) was added to the mixture and the two 
layers were separated. The ether layer was dried (magnesium sulfate) and evaporated under 
reduced pressure to afford compounds 2a-c as pure solids. 
[6-Chloro-2-(dimethylamino)-5-methylpyrimidin-4-yl](2,6-difluoro-phenyl) acetonitrile (2a): 
Yield: 1.56 g, 97%; m.p.: 120–122°C; 1H NMR (300 MHz, CDCl3): δ = 2.19 (s, 3H, CH3), 3.08 (s, 
6H, (CH3)2N)), 5.54 (s, 1H, CH-CN), 6.96 (t, 2H, J = 8.3 Hz, Harom), 7.31–7.41 (m, 1H, Harom); 13C 
NMR (75 MHz, CDCl3): δ = 13.21 (CH3), 32.17 (CH-CN), 36.71 ((CH3)2N), 109.75 (t, J = 17.2 
Hz, Carom), 111.79 (dd, J = 3.0, 22.5 Hz, Carom), 112.04 (C5), 115.67 (CN), 130.96 (t, J = 40.5 Hz, 
Carom), 159.46 (C6), 159.60 (C4), 162.31 (C2), 160.74 (dd, J = 6.6, 252.2 Hz, Carom); HR-MALDI 
MS m/z calcd  for C15H14ClF2N4: 323.0875 [M+H]+ , found 323.0863. Anal. calcd for 
C15H14ClF2N4 (322.74): C 55.82, H 4.06, N 17.36, found: C 55.97, H 4.00, N 17.11. 
2-(6-Chloro-2-(dimethylamino)-5-methylpyrimidin-4-yl)-2-(3,5-dimethylphenyl)acetonitrile 
2b: Yield: 1.54 g, 98%; m.p.: 108–109°C; 1H NMR (300 MHz, CDCl3): δ = 2.10 (s, 3H, CH3), 
2.30 (s, 6H, (CH3)2Ar), 3.21 (s, 6H, (CH3)2N), 5.16 (s, 1H, CHCN), 6.95 (s, 1H, Harom), 6.98 (s, 
2H, Harom); 13C NMR (75 MHz, CDCl3): δ = 13.53 (CH3), 21.24 ((CH3)2Ar), 36.94 ((CH3)2N), 43.24 
(HCCN), 112.11 (C-5), 118.18 (CN), 125.54, 130.29, 132.66, 138.90 (Carom), 159.68 (C-6), 
162.32 (C-4), 162.42 (C-2); EI-MS m/z (%) 313.90 [M]+ (100). Anal. calcd for C17H19N4Cl: 
(313.90): C 64.86, H 6.08, N 17.80, found: C 64.75, H 6.14, N 17.98. 
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[6-Chloro-2-(dimethylamino)-5-methylpyrimidin-4-yl](mesityl)acetonitrile 2c: Yield: 1.41 g, 
86%; m.p.: 140–142°C; 1H NMR (300 MHz, CDCl3): δ = 1.80 (s, 3H, CH3-C5), 2.26 (s, 9H, 3 
(CH3)3Ar), 3.18 (s, 6H, (CH3)2N), 5.50 (s, 1H, CH), 6.87 (s, 2H, Harom); 13C NMR (75 MHz, 
CDCl3): δ = 12.83 (CH3-C5), 20.82 (CH3Ar), 20.93 ((CH3)2Ar), 36.84 (CH-CN), 40.13 ((CH3)2N), 
112.23 (C5), 117.08 (CN), 127.02, 130.34, 137.01, 138.41 (Carom), 159.28 (C2), 162.28 (C4), 
162.43 (C6); HR-MALDI MS m/z calcd for C18H22ClN4 (329.1528) [M+H]+ , found 329.1525. 
General procedure for the synthesis of 6-aryl-2-(dimethylamino)-5-methylpyrimidin-4(3H)-
ones 3a-c: A solution of 2a-c (2.5 mmol) in concentrated hydrochloric acid (20 mL), acetic acid 
(10 mL) and water (10 mL) was refluxed at 115°C for 40 h. The solvent was evaporated under 
reduced pressure, and the residual material was treated with water (20 mL) and neutralized with 
10% sodium hydroxide. The solid product formed was filtered and dried to afford the pure 
compounds 3a-c. 
6-(2,6-Difluorobenzyl)-2-(dimethylamino)-5-methylpyrimidin-4(3H)-one 3a: Yield: 0.59 g, 
84%; m.p.: 208–210°C [237–238°C (CH3CN)] [20]; 1H NMR (300 MHz, [D6]DMSO): δ = 1.94 (s, 
3H, CH3), 2.82 (s, 6H, (CH3)2N), 3.78 (s, 2H, CH2Ar), 7.03 (t, 2H, J = 7.7 Hz, Harom), 7.25–7.35 
(m, 1H, Harom); 13C NMR (75 MHz, [D6]DMSO): δ =  9.66 (CH3), 27.04 (CH2Ph), 36.33 ((CH3)2N), 
110.62–110.95 (m, Carom), 128.30 (t, J = 10.0 Hz, Carom), 161.61 (dd, J = 8.3, 245.0 Hz, Carom); 
HR-MALDI MS m/z calcd for C14H16F2N3O (280.1256) [M+H]+ , found 280.1247. Anal. calcd for 
C14H15F2N3O (279.29): C 60.21, H 5.41, N 15.05, found: C 59.93, H 5.32, N 14.71. 
2-(Dimethylamino)-6-(3,5-dimethylbenzyl)-5-methylpyrimidin-4(3H)-one 3b: Yield: 0.60 g, 
89% as a white solid; m.p.: 163–164°C; 1H NMR (300 MHz, [D6]DMSO): δ = 1.83 (s, 3H, CH3), 
2.21 (s, 6H, (CH3)2Ar), 2.99 (s, 6H, (CH3)2N), 3.64 (s, 2H, CH2), 6.79 (s, 1H, Harom), 6.85 (s, 2H, 
Harom), 10.89 (s, 1H, NH); 13C NMR (75 MHz, [D6]DMSO): δ = 10.13 (CH3), 20.88 ((CH3)2Ar), 
36.82 ((CH3)2N), 40.68 (CH2), 126.29, 127.37, 136.95, 138.41 (Carom); HR-MALDI MS m/z calcd 
for C16H22N3O (272.1757) [M+H]+ , found 272.1745. 
2-(Dimethylamino)-6-(mesitylmethyl)-5-methylpyrimidin-4(3H)-one 3c: Yield: 0.58 g, 82%; 
m.p.: 223–225°C; 1H NMR (300 MHz, [D6]DMSO): δ = 1.96 (s, 3H, CH3-C5), 2.16 (s, 3H, 
CH3Ar), 2.19 (s, 6H, (CH3)2Ar), 2.80 (s, 6H, (CH3)2N), 3.66 (s, 2H, CH2Ar); 13C NMR (75 MHz, 
[D6]DMSO): δ = 9.75 (CH3-C5), 20.02 ((CH3)2Ar), 20.39 (CH3Ar), 33.23 (CH2Ar), 36.47 
((CH3)2N), 127.82, 133.12, 133.96, 136.37 (Carom), EI-MS m/z (%) 285 [M+] (60), 270 (100). 
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Anal. calcd for C17H23N3O×0.2 H2O (289): C 70.65, H 8.16, N 14.54, found: C 70.55, H 8.23, N 
14.21. 
Synthesis of [6-chloro-2-(dimethylamino)-5-methylpyrimidin-4-yl](2,6-difluorophenyl) 
methanone 4a: Sodium (0.08 g, 3.7 mmol) was dissolved in methanol (3 mL) and added to a 
stirred solution of compound 2a (1.00 g, 3.0 mmol) in dry toluene (40 mL). A stream of oxygen 
was bubbled through the reaction mixture with refluxing at 120oC for 12 h. The solvent was 
removed under reduced pressure. The residual material was treated with a mixture of petroleum 
ether/ether (5:1, v/v, 15 mL). The precipitated material was filtered and dried to afford 0.49 g of 
compound 4a, yield: 52%; as greenish yellow crystals; m.p.: 118–120°C; 1H NMR (300 MHz, 
CDCl3): δ = 2.40 (s, 3H, CH3), 3.00 (s, 6H, (CH3)2N), 6.94 (t, 2H, J = 8.1 Hz, Harom), 7.38–7.47 
(m, 1H, Harom); 13C NMR (75 MHz, CDCl3): δ = 13.36 (CH3), 36.76 ((CH3)2N), 111.41–111.75 (m, 
Carom), 113.85 (C5), 132.65 (t, J = 10.4 Hz, Carom), 159.55 (C4), 160.03 (C2), 160.59 (dd, J = 7.2, 
254.2 Hz, Carom), 163.62 (C6); EI-MS m/z (%): 311 [M+] (100). Anal. calcd for C14H12ClF2N3O 
(311.71): C 53.94, H 3.88, N 13.48, found: C 54.30, H 3.61, N 13.42. 
Synthesis of (6-chloro-2-(dimethylamino)-5-methylpyrimidin-4-yl)(3,5-dimethylphenyl)-
methanone 4b: To a mixture of compound 1 (2.06 g, 10 mmol) and (3,5-
dimethylphenyl)acetonitrile (1.60 g, 11 mmol) in dimethylformamide (50 mL) was added sodium 
hydride (55% suspension in paraffin oil, 1.09 g, 25 mmol) portionwise. After stirring for 2 h at 
room temperature, the reaction mixture was stirred for another 4 h under a stream of oxygen. 
The mixture was quenched by addition of water (2 mL) dropwise followed by addition of water 
(25 mL) and ether (30 mL) for separation of the two layers. The ether layer was dried 
(magnesium sulfate), and evaporated under reduced pressure. The resulting solid was purified 
by addition of methanol (5 mL), filtered and dried to afford compound 4b as a pure solid. The 
filtrate was evaporated under reduced pressure, methanol (5 mL) was added to the residual 
material and stirred. The pure solid product was filtered off, washed with methanol and dried to 
afford 3.00 g of 4b, yield: 99% as a pale yellow solid; m.p.: 108–110°C; 1H NMR (300 MHz, 
CDCl3): δ = 2.06 (s, 3H, CH3), 2.36 (s, 6H, (CH3)2Ar), 3.14 (s, 6H, (CH3)2N), 7.26 (s, 1H, Harom), 
7.48 (s, 2H, Harom); 13C NMR (75 MHz, CDCl3): δ = 13.53 (CH3), 21.15 ((CH3)2Ar), 37.03 
((CH3)2N), 111.91 (C-5), 127.86, 134.82, 135.97, 138.42 (Carom), 159.74 (C-6), 162.29 (C-4), 
164.65 (C-2), 194.12 (CO); HR-MALDI MS m/z calcd for C16H19N3OCl (304.1211) [M+H]+ , found 
304.1215. 
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Synthesis of 6-aroyl-2-(dimethylamino)-5-methylpyrimidin-4(3H)-ones 5a,b: A solution of 
compound 4a,b (3 mmol) in concentrated hydrochloric acid (20 mL), acetic acid (10 mL) and 
water (10 mL) was refluxed at 115°C for 40 h. The solvent was evaporated under reduced 
pressure, the residual material was treated with water (20 mL) and neutralized with 10% sodium 
hydroxide. The solid product formed was filtered and dried to afford compounds 5a,b as pure 
solids. 
6-(2,6-Difluorobenzoyl)-2-(dimethylamino)-5-methylpyrimidin-4(3H)-one 5a: Yield: 0.70 g, 
80%; as a pale yellow solid; m.p.: 202–204°C; 1H NMR (300 MHz, [D6]DMSO): δ = 2.05 (s, 3H, 
CH3), 2.85 (s, 6H, (CH3)2N), 7.19 (t, 2H, J = 8.3 Hz, Harom), 7.56–7.65 (m, 1H, Harom), 11.41 (bs, 
1H, NH); 13C NMR (75 MHz, [D6]DMSO): δ = 9.77 (CH3), 36.59 ((CH3)2N), 111.57–111.90 (m, 
Carom), 132.99 (t, J = 10.5 Hz, Carom), 159.12 (dd, J = 7.7, 249.9 Hz, Carom), 190.94 (C=O); EI-MS 
m/z (%) 293 [M+] (100). Anal. calcd for C14H13F2N3O2 (293.27): C 57.34, H 4.47, N 14.33, found: 
C 57.45, H 4.38, N 14.05. 
2-(Dimethylamino)-6-(3,5-dimethylbenzoyl)-5-methylpyrimidin-4(3H)-one 5b: Yield: 0.80 g, 
94%; m.p.: 200–202ºC; 1H NMR (300 MHz, [D6]DMSO): δ = 1.66 (s, 3H, CH3-C5), 2.32 [s, 6H, 
(CH3)2Ar], 2.30 [s, 6H, (CH3)2N], 7.32 (s, 1H, Harom), 7.47 (s, 2H, Harom), 11.27 (bs, 1H, NH); 13C 
NMR (75 MHz, [D6]DMSO): δ = 10.00 (CH3-C5), 20.63 ((CH3)2Ar), 37.02 ((CH3)2N), 127.05, 
134.69, 135.53, 138.19 (Carom), 194.70 (C=O); EI-MS m/z (%) 285 [M+] (35), 270 (100). Anal. 
calcd for C16H19N3O2×0.25 H2O (289.85): C 66.30, H 6.78, N 14.50, found: C 66.45, H 6.65, N 
14.41. 
Synthesis of 1-[6-chloro-2-(dimethylamino)-5-methylpyrimidin-4-yl]-1-(aryl)-ethanol 6a,b: 
To a solution of 4a,b (16.5 mmol) in ether (70 mL) was added methyl magnesium bromide (3M 
in ether, 11 mL, 33.0 mmol) and the reaction mixture was stirred for 14 h under nitrogen at room 
temperature. The reaction was quenched by addition of saturated ammonium chloride (5 mL) 
followed by addition of water (15 mL) and ether (15 mL). The ether layer was separated, dried 
(magnesium sulfate) and evaporated under reduced pressure. The resulting solid was purified 
by addition of petroleum ether (5 mL) and 6a,b was obtained by filtration and drying. The filtrate 
was evaporated under reduced pressure and petroleum ether (5 mL) was added to the residual 
material, filtered, and repeated two times to give pure compounds 6a,b. 
1-[6-Chloro-2-(dimethylamino)-5-methylpyrimidin-4-yl]-1-(2,6-difluorophenyl)-ethanol 6a: 
Yield: 4.42 g, 82%; m.p.: 92–94°C; 1H NMR (300 MHz, CDCl3): δ = 1.83 (s, 3H, CH3-C5), 1.92 
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(t, 3H, JHF = 3.9 Hz, CH3-C-OH), 3.22 (s, 6H, (CH3)2N), 6.69 (s, 1H, OH), 6.83 (t, 2H, J = 8.2 Hz, 
Harom), 7.18–7.27 (m, 1H, Harom); 13C NMR (75 MHz, CDCl3): δ = 13.59 (CH3), 28.25 (t, J = 22.6 
Hz, CH3-C-OH), 37.19 ((CH3)2N), 72.96 (C-OH), 99.97 (t, J = 17.8 Hz, Carom),  110.27 (C5), 
112.13–112.50 (m, Carom), 129.59 (t, J = 45.5 Hz, Carom), 158.03 (C2), 161.45 (dd, J = 8.5, 251.5 
Hz, Carom), 163.34 (C4), 171.13 (C6); HR-MALDI MS m/z calcd for C15H17ClF2N3O (328.1023) 
[M+H]+ , found 328.1018. Anal. calcd for C15H16ClF2N3O (327.76): C 54.97, H 4.92, N 12.82, 
found: C 55.23, H 4.69, N 12.80. 
Synthesis of 1-[6-chloro-2-(dimethylamino)-5-methylpyrimidin-4-yl]-1-(3,5-
dimethylphenyl)-ethanol 6b: Yield: 3.11 g (59%) as a white solid; m.p.: 109–110°C; 1H NMR 
(300 MHz, CDCl3): δ = 1.76 (s, 3H, CCH3), 1.85 (s, 3H, CH3), 2.28 (s, 6H, (CH3)2Ar), 3.24 (s, 6H, 
(CH3)2N), 6.42 (s, 1H, OH), 6.89 (s, 3H, Harom); 13C NMR (75 MHz, CDCl3): δ = 14.55 (CH3), 
21.40 ((CH3)2Ar), 25.69 (CCH3), 37.21 ((CH3)2N), 74.63 (C-OH), 111.83 (C-5), 124.03, 129.22, 
137.86, 144.03 (Carom), 157.89 (C-6), 163.43 (C-4), 171.77 (C-2); HR-MALDI MS m/z calcd for 
C17H22ClNaN3O (342.1344) [M+Na]+ , found 342.1347. 
Synthesis of 4-Chloro-6-[1-(aryl)vinyl]-N,N,5-trimethylpyrimidin-2-amine 7a,b: Method A: A 
solution of 6a,b (6.26 mmol) and phosphorus pentoxide (5.0 g, 35.2 mmol) in dichloromethane 
(50 mL) was stirred for 20 h at room temperature, followed by slowly addition of water (200 mL). 
The two layers were separated and the organic layer was evaporated under reduced pressure 
to afford compound 7a as a pure solid. For compound 7b, the residual material from 
evaporation of the organic layer was purified by a silica gel column using petroleum ether/ether 
(5:1, v/v) as eluent. 
Method B: A solution of 6b (3.00 g, 9.40 mmol) and phosphorus oxychloride (4 mL, 21.20 
mmol) in dichloromethane (50 mL) was refluxed at 45°C for 20 h. Then the solvent was 
evaporated under reduced pressure followed by addition of water (70 mL). After addition of 
ether, the two layers were separated. The ether layer was dried (magnesium sulfate) then the 
solvent was evaporated under reduced pressure and the residual material was 
chromatographed on a silica gel column using petroleum ether / ether (2:1, v/v) to afford 
compound 7b. 
Method C: To a suspension of magnesium (0.19 g, 8 mmol) and titanium tetrachloride (0.38 g, 
0.21 mL, 2 mmol) in dichloromethane (4 mL) was added dry THF (2 mL) over a 2 min period. 
After being stirred for 20 minutes at 0°C, a solution of 4b in dichloromethane (3 mL) was added 
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dropwise. After stirring for 30 min at 0°C, the reaction mixture was stirred for an additional 30 
min at room temperature and cooled to 0°C. Saturated potassium carbonate solution (10 mL) 
was added and the mixture was diluted with ether (20 mL). The organic layer was separated, 
dried and removed under reduced pressure. The residual material was chromatographed on a 
silica gel column using petroleum ether / ether (2:1, v/v) to afford compounds 7b and 8. 
4-Chloro-6-[1-(2,6-difluorophenyl)vinyl]-N,N,5-trimethylpyrimidin-2-amine 7a: Yield: 1.26 g, 
65%; m.p.: 88–90°C; 1H NMR (300 MHz, CDCl3): δ = 2.14 (s, 3H, CH3), 3.06 (s, 6H, (CH3)2N), 
5.88 (s, 1H, HCH=C), 5.92 (s, 1H, HCH=C), 6.88 (t, 2H, J = 8.1 Hz, Harom), 7.18–7.28 (m, 1H, 
Harom); 13C NMR (75 MHz, CDCl3): δ = 14.85 (CH3), 36.81 ((CH3)2N), 111.13–111.47 (m, Carom), 
112.27 (C5), 125.92 (CH2=C), 129.12 (t, J = 10.3 Hz, Carom), 135.81 (CH2=C), 160.33 (dd, J = 
7.2, 249.4 Hz, Carom), 159.73 (C4), 162.60 (C2), 166.59 (C6); HR-MALDI MS m/z calcd for 
C15H15ClF2N3 (310.0917) [M+H]+ , found 310.0917. Anal. calcd for C15H14ClF2N3 (309.74): C 
58.16, H 4.56, N 13.57, found: C 58.50, H 4.44, N 13.58. 
6-Chloro-4-[1-(3,5-dimethylphenyl)vinyl]-N,N,5-trimethylpyrimidin-2-amine 7b: Yield: 43% 
(method A), 74% (method B), 7% (method C) as a white solid; m.p.: 65–67°C. 1H NMR (300 
MHz, CDCl3): δ = 1.96 (s, 3H, CH3), 2.28 (s, 6H, (CH3)2Ar), 3.17 (s, 6H, (CH3)2N), 5.30 (s, 1H, 
CH2), 5.81 (s, 1H, CH2), 6.91 (s, 3H, Harom); 13C NMR (75 MHz, CDCl3): δ = 14.79 (CH3), 21.30 
[(CH3)2Ar], 37.08 ((CH3)2N), 113.34 (C-5), 115.89 (CH2=C), 124.03, 129.77, 137.92 
(Carom),147.42 (CH2=C and Carom), 160.15 (C-6), 161.60 (C-4), 168.60 (C-2); HR-MALDI MS m/z 
calcd for C17H21ClN3 (302.1419) [M+H]+ , found 302.1418. 
[6-Chloro-2-(dimethylamino)-5-methylpyrimidin-4-yl](3,5-dimethylphenyl)methanol 8: 
Yield: 82 mg (27%) as a white solid; m.p.: 85–87°C; 1H NMR (300 MHz, CDCl3): δ = 1.94 (s, 3H, 
CH3), 2.27 (s, 6H, (CH3)2Ar), 3.23 (s, 6H, (CH3)2N), 5.40 (d, 1H, HCOH), 5.53 (d, 1H, HCOH), 
6.85 (s, 2H, Harom), 6.90 (s, 1H, Harom); 13C NMR (75 MHz, CDCl3): δ = 12.96 (CH3), 21.25 
((CH3)2Ar), 37.19 ((CH3)2N), 72.49 (CH-OH), 111.83 (C-5), 125.34, 129.81, 138.22, 140.74 
(Carom), 158.80 (C-6), 161.93 (C-4), 167.99 (C-2); HR-MALDI MS m/z calcd for C16H23ClN3O 
(308.1524) [M+H]+ , found 308.1520. 
Reduction of 6-chloro-4-[1-(3,5-dimethylphenyl)vinyl]-N,N,5-trimethylpyrimidin-2-amine 
7b: synthesis of 9 and 10: A suspension of 7b (0.71 g, 2.35 mmol) and 10% Pd/C (0.41 mg) 
dissolved in ethanol (30 mL) was reduced in an autoclave under 3.5 bar of hydrogen for 4 h 
followed by filtration with boiling ethanol. The solvent was evaporated under reduced pressure. 
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After addition of water (25 mL) and a solution of potassium carbonate (2 mL) to appoint pH ≈ 7, 
the solvent was evaporated under reduced pressure again and the combined residual materials 
were chromatographed on a silica gel column using petroleum ether/ether (2:1, v/v) to afford 
compounds 9 and 10. 
4-Chloro-6-[1-(3,5-dimethylphenyl)ethyl]-N,N,5-trimethylpyrimidin-2-amine 9: Yield: 37 mg 
(5%) as a white solid; m.p.: 60–62°C; 1H NMR (300 MHz, CDCl3): δ = 1.56 (d, 3H, J = 6.9 Hz, 
CH3CH), 2.10 (s, 3H, CH3), 2.26 (s, 6H, (CH3)2Ar), 3.19 (s, 6H, (CH3)2N), 4.14 (q, 1H, J = 6.9 
Hz, CH3CH), 6.82 (s, 1H, Harom), 6.87 (s, 2H, Harom); 13C NMR (75 MHz, CDCl3): δ = 13.55 (CH3), 
21.34 ((CH3)2Ar and CHCH3), 36.94 ((CH3)2N), 43.92 (CHCH3), 112.91 (C-5), 125.57, 128.11, 
137.82, 143.75 (Carom), 159.93 (C-6), 161.06 (C-4), 171.71 (C-2); HR-MALDI MS m/z calcd for 
C17H23ClN3 (304.1575) [M+H]+ , found 304.1576. 
4-[1-(3,5-Dimethylphenyl)ethyl]-N,N,5-trimethylpyrimidin-2-amine 10: Yield: 85 mg (13%) 
obtained as yellow oil; 1H NMR (300 MHz, CDCl3): δ = 1.58 (d, 3H, J = 7.0 Hz , CH3CH), 1.99 (s, 
3H, CH3), 2.26 (s, 6H, (CH3)2Ar), 3.20 (s, 6H, (CH3)2N), 4.07 (q, 1H, J = 7.0 Hz, CH3CH), 6.81 
(s, 1H, Harom), 6.90 (s, 2H, Harom), 7.95 (s, 1H, H-6); 13C NMR (75 MHz, CDCl3): δ = 14.60 (CH3), 
20.95 (CHCH3), 21.34 ((CH3)2Ar), 37.07 ((CH3)2N), 43.44 (CHCH3), 115.12 (C-5), 125.71, 
127.96, 137.69, 144.09 (Carom), 157.76 (C-6), 161.41 (C-4), 170.01 (C-2); HR-MALDI MS m/z 
calcd for C17H24N3 (270.1965) [M+H]+ , found 270.1972. 
General procedure for the synthesis of 6-[1-(aryl)vinyl]-2-(dimethylamino)-5-
methylpyrimidin-4(3H)-ones 11a,b: A solution of 7a,b (3.1 mmol) in concentrated hydrochloric 
acid (20 mL), acetic acid (10 mL) and water (10 mL) was refluxed at 115°C for 42 h. The solvent 
was evaporated under reduced pressure and the residue was dissolved in water (40 mL) and 
neutralized with 10% sodium hydroxide. The solid product formed was filtered and dried to 
afford 11a,b. 
6-[1-(2,6-Difluorophenyl)vinyl]-2-(dimethylamino)-5-methylpyrimidin-4(3H)-one 11a: Yield: 
0.63 g, 70%; m.p.: 173–175°C; 1H NMR (300 MHz, [D6]DMSO): δ = 1.84 (s, 3H, CH3), 2.88 (s, 
6H, (CH3)2N), 5.74 (s, 1H, HCH=C), 5.89 (s, 1H, HCH=C), 7.08 (t, 2H, J = 8.1 Hz, Harom), 7.34–
7.44 (m, 1H, Harom), 11.03 (bs, 1H, NH); 13C NMR (75 MHz, [D6]DMSO): δ = 11.30 (CH3), 36.44 
((CH3)2N), 111.15–111.49 (m, Carom), 124.61 (CH2=C), 129.54 (t, J = 10.5 Hz, Carom), 135.63 
(CH2=C), 159.69 (d, J = 7.3, 246.9 Hz, Carom); EI-MS m/z (%) 291 [M]+ (100). Anal. calcd for 
C15H15F2N3O×0.2H2O (294.91): C 61.09, H 5.26, N 14.25, found: C 61.13, H 5.08, N 14.27. 
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2-(Dimethylamino)-6-[1-(3,5-dimethylphenyl)vinyl]-5-methylpyrimidin-4(3H)-one 11b: Yield: 
0.78 g (89%) as a white solid; m.p.: 183–185°C; 1H NMR (300 MHz, [D6]DMSO): δ = 1.67 (s, 
3H, CH3), 2.26 (s, 6H, (CH3)2Ar), 2.99 (s, 6H, (CH3)2N), 5.18 (s, 1H, C=CH2), 5.77 (s, 1H, 
C=CH2), 6.93 (s, 1H, Harom), 6.98 (s, 2H, Harom), 11.08 (bs, 1H, NH); 13C NMR (75 MHz, 
[D6]DMSO): δ = 11.42 (CH3), 20.93 ((CH3)2Ar), 36.97 ((CH3)2N), 105.86 (C-5), 114.69 (C=CH2), 
123.69, 129.28, 137.33, 138.03 (Carom), 146.93 (C=CH2); HR-MALDI MS m/z calcd for 
C17H21N3NaO (306.1577) [M+Na]+ , found 306.1571. 
General procedure for the synthesis of 6-[1-(aryl)ethyl]-2-(dimethylamino)-5-
methylpyrimidin-4(3H)-ones 12a,b: A suspension of 11a,b (2.3 mmol) and 10% Pd/C (0.40 g) 
in ethanol (40 mL) was reduced in an autoclave under 3.5 bar of hydrogen for 5 h. After filtration 
with boiling ethanol, the solvent was evaporated under reduced pressure to give 12a,b. 
6-[1-(2,6-Difluorophenyl)ethyl]-2-(dimethylamino)-5-methylpyrimidin-4(3H)-one (12a) [MC-
1220]: Yield: 0.65 g, 97%; m.p.: 166–168°C [174–176°C].[12] 1H-NMR (300 MHz, CDCl3) δ = 
1.61 (d, 3H, J = 7.2 Hz, CH3CH), 1.89 (s, 3H, CH3), 3.09 (s, 6H, (CH3)2N), 4.52 (s, 1H, J = 7.2 
Hz, CH3CH), 6.80 (t, 2H, J = 8.3 Hz, Harom), 7.08–7.26 (m, 1H, Harom), 11.66 (bs, 1H, NH); 13C-
NMR (75 MHz, CDCl3) δ = 9.20 (CH3CH), 17.54 (CH3), 34.29 (CH), 37.06 ((CH3)2N), 105.14 
(C5), 111.22 (dd, J = 8.2, 18.6 Hz, Carom), 119.67 (t, J = 17.6 Hz, Carom), 127.58 (t, J = 10.7 Hz, 
Carom), 151.91 (C2), 161.76 (dd, J = 9.0, 248.1 Hz, Carom), 166.01 (C4), 166.30 (C6); EI MS m/z: 
293 (100%, M+).  
2-(Dimethylamino)-6-[1-(3,5-dimethylphenyl)ethyl]-5-methylpyrimidin-4(3H)-one 12b: 
Yield: 0.55 g, 84% as a white solid; m.p.: 172–174°C; 1H NMR (300 MHz, [D6]DMSO): δ = 1.42 
(d, 3H, J = 6.9 Hz, CH3CH), 1.84 (s, 3H, CH3), 2.21 (s, 6H, (CH3)2Ar), 3.03 (s, 6H, (CH3)2N), 
4.05 (q, 1H, J = 6.9 Hz, CH3CH), 5.18 (s, 1H, C=CH2), 6.78 (s, 1H, Harom), 6.95 (s, 2H, Harom), 
10.89 (bs, 1H, NH); 13C NMR (75 MHz, [D6]DMSO): δ = 9.58 (CH3), 20.31 (CH3CH), 20.97 
((CH3)2Ar), 36.75 ((CH3)2N), 41.68 (CH3CH), 125.31, 127.42, 136.75, 144.26 (Carom); HR-MALDI 
MS m/z calcd for C17H24N3O (286.1914) [M+H]+ , found 286.1903. 
General procedure for the synthesis of 4-(1-(aryl)ethyl)-6-methoxy-N,N,5-
trimethylpyrimidin-2-amines 13a,b: Sodium hydride (0.05 g, 55% suspension in paraffin oil, 
1.2 mmol) was added portionwise to a solution of 12a,b (1.0 mmol) in dry dimethylformamide (5 
mL) at room temperature, stirred for 0.5 h followed by addition of methyl iodide (0.07 mL, 1.1 
mmol). The reaction mixture was stirred for 2 h then poured on cold water (25 mL) and stirred 
for 0.5 h. Compound 13a was precipitated, filtered and dried. For compound 13b, ether (30 mL) 
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was added to the reaction mixture and extracted and the ether layer was dried (magnesium 
sulfate). The solvent was removed under reduced pressure to afford compound 13b as pure oil 
4-(1-(2,6-Difluorophenyl)ethyl)-6-methoxy-N,N,5-trimethylpyrimidin-2-amine 13a: Yield: 
0.28 g, 91% as a white solid; m.p.: 65–66°C; 1H NMR (300 MHz, CDCl3): δ = 1.65 (d, 3H, J = 
7.1 Hz, CH3CH), 1.90 (s, 3H, CH3), 3.09 (s, 6H, (CH3)2N], 3.87 (s, 3H, OCH3), 4.58 (s, 1H, J = 
7.1 Hz, CH3CH), 6.78 (t, 2H, J = 8.2 Hz, Harom), 7.05–7.14 (m, 1H, Harom); 13C NMR (75 MHz, 
CDCl3): δ = 8.93 (CH3CH), 17.81 (CH3-C5), 33.83 (CH), 36.55 ((CH3)2N), 52.99 (OCH3), 100.61 
(C5), 111.23 (dd, J = 8.2, 18.6 Hz, Carom), 120.18 (t, J = 17.5 Hz, Carom), 127.50 (t, J = 10.5 Hz, 
Carom), 159.94 (C2), 161.68 (dd, J = 8.9, 248.2 Hz, Carom), 167.67 (C4), 168.14 (C6); HR-MALDI 
MS m/z calcd for C16H20F2N3O (308.1569) [M+H]+ , found 308.1575. 
4-(1-(3,5-Dimethylphenyl)ethyl)-6-methoxy-N,N,5-trimethylpyrimidin-2-amine 13b:  Yield: 
0.18 g (86%) obtained as yellow oil; 1H NMR (300 MHz, CDCl3): δ = 1.56 (d, 3H, J = 6.9 Hz, 
CH3CH), 1.94 (s, 3H, CH3), 2.26 (s, 6H, (CH3)2Ar), 3.17 (s, 6H, (CH3)2N), 3.86 (s, 3H, OCH3), 
4.13 (q, 1H, J = 6.9 Hz, CH3CH),), 6.79 (s, 1H, Harom), 6.95 (s, 2H, Harom); 13C NMR (75 MHz, 
CDCl3): δ = 9.30 (CH3), 21.16 ((CH3)2Ar), 21.36 (CH3CH), 36.74 ((CH3)2N), 42.54 (CH3CH), 
52.95 (OCH3), 100.92 (C-5), 125.66, 127.72, 137.47, 144.94 (Carom), 160.12 (C-4), 168.16 (C-2), 
169.31 (C-6); EI MS m/z: 299.3 (100%, M+); HR-MALDI MS m/z calcd for C18H26N3O (300.2070) 
[M+H]+ , found 300.2078.  
